Gritstone bio announced that the Compensation Committee of the company’s Board of Directors granted five employees nonqualified stock options to purchase an aggregate of 83,300 shares of its common stock with an exercise price of $2.06, which is equal to the closing price of Gritstone’s common stock on June 2, 2023, the last trading day preceding the day of the approval. These stock options are part of an inducement material to the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees’ date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees’ continued employment with Gritstone on such vesting dates. The stock options are subject to the terms and conditions of Gritstone’s 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GRTS:
- Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications
- Gritstone bio to Participate in Upcoming Investor Conferences
- Cantor biopharma/biotech analysts to hold an analyst/industry conference call
- Gritstone presents advances in neoantigen vaccine programs, capabilities